NYSE:GKOSGlaukos Stock Price, Forecast & News

Glaukos' stock was trading at $38.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GKOS shares have increased by 5.0% and is now trading at $40.58. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 3 sell ratings, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Glaukos.

Glaukos is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Glaukos.

Glaukos Corp (NYSE:GKOS) issued its earnings results on Thursday, May, 7th. The medical instruments supplier reported ($0.44) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.09. The medical instruments supplier earned $55.30 million during the quarter, compared to the consensus estimate of $55.05 million. Glaukos had a negative return on equity of 6.95% and a negative net margin of 15.65%. The company's revenue for the quarter was up 2.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.04) EPS. View Glaukos' earnings history.

Glaukos updated its first quarter 2020 Pre-Market earnings guidance on Thursday, April, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $55-55.3 million, compared to the consensus revenue estimate of $60.81 million.

9 equities research analysts have issued 12 month target prices for Glaukos' stock. Their forecasts range from $34.00 to $67.00. On average, they expect Glaukos' stock price to reach $47.63 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price. View analysts' price targets for Glaukos.

News stories about GKOS stock have been trending very positive this week, according to InfoTrie. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Glaukos earned a news sentiment score of 3.8 on InfoTrie's scale. They also assigned news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutGlaukos.

Some companies that are related to Glaukos include Hill-Rom (HRC), Novocure (NVCR), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), Nevro (NVRO), ICU Medical (ICUI), Irhythm Technologies (IRTC), NuVasive (NUVA), Merit Medical Systems (MMSI), Inovio Pharmaceuticals (INO), Inspire Medical Systems (INSP) and AtriCure (ATRC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include Alibaba Group (BABA), NVIDIA (NVDA), PTC Therapeutics (PTCT), Paypal (PYPL), Marvell Technology Group (MRVL), Boeing (BA), Micron Technology (MU), Shopify (SHOP), Baidu (BIDU) and Caterpillar (CAT).

(GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Glaukos' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (13.22%), Brown Capital Management LLC (10.42%), Baillie Gifford & Co. (8.25%), Fred Alger Management LLC (6.47%), Janus Henderson Group PLC (5.41%) and State Street Corp (2.99%). Company insiders that own Glaukos stock include Chris M Calcaterra, Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link. View institutional ownership trends for Glaukos.

GKOS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Invesco Ltd., Jennison Associates LLC, Wells Fargo & Company MN, Deutsche Bank AG, Rhenman & Partners Asset Management AB, and C WorldWide Group Holding A S. Company insiders that have sold Glaukos company stock in the last year include Joseph E Gilliam, and Thomas William Burns. View insider buying and selling activity for Glaukos.

GKOS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Henderson Group PLC, Fred Alger Management LLC, State Street Corp, Bank of New York Mellon Corp, Wasatch Advisors Inc., Legal & General Group Plc, and Public Sector Pension Investment Board. View insider buying and selling activity for Glaukos.

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GKOS stock can currently be purchased for approximately $40.58.

Glaukos has a market capitalization of $1.79 billion and generates $236.98 million in revenue each year. The medical instruments supplier earns $15.42 million in net income (profit) each year or ($0.10) on an earnings per share basis. Glaukos employs 437 workers across the globe.

The official website for Glaukos is www.glaukos.com.

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]